Multiple Sclerosis

A national strategy of early initiation of highly effective disease-modifying therapy was associated with improved outcomes in patients with relapsing-remitting multiple sclerosis compared with an escalation strategy, according to a recent study.
Read More

On March 19, 2021, Janssen Pharmaceutical Companies announced that the US Food and Drug Administration approved ponesimod for the treatment of relapsing multiple sclerosis in adults. The approval indications include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Read More

Researchers found that depression increased the risk of vascular disease and all-cause mortality in patients with multiple sclerosis, according to a recent study.
Read More

The trajectory of results on at-home computerized tests for cognition may identify patients at risk for disability progression due to relapsing-remitting multiple sclerosis, according to a recent study.
Read More

Black patients with multiple sclerosis had greater disease severity than white patients after adjusting for socioeconomic status, according to a recent study in the United States.
Read More

Patients with multiple sclerosis who were recently treated with anti-CD20 monoclonal antibody therapies had reduced antibody and B-cell responses but intact T-cell responses to SARS-CoV-2 mRNA vaccination compared with healthy people.
Read More

Previous small studies have suggested that disability and age are associated with the severity of SARS-CoV-2 infections in patients with multiple sclerosis (MS). More detailed analysis from a larger and more diverse population would aid healthcare providers in identifying which patients require more careful monitoring.
Read More

A comparative effectiveness study of real-world data from patients with multiple sclerosis showed that dimethyl fumarate and fingolimod were equivalent and rituximab was superior to natalizumab for reducing relapse.
Read More

The FDA approved a new intramuscular injection route of administration for Plegridy (peginterferon beta-1a) for the treatment of relapsing forms of multiple sclerosis.
Read More

Clinicians and patients should consider the immune-modulating effects of various disease-modifying therapies and their implications for COVID-19 susceptibility and vaccine-generated immune response.
Read More

Page 1 of 4

Subscribe to Value-Based Care in Neurology

Stay up to date with the latest news in neurology by subscribing to receive the free VBCN e‑Newsletter.